The study by Liao et al. demonstrated that RA can reverse the resistance of non-small cell lung cancer (NSCLC) to cisplatin by activating the MAPK signaling pathway, specifically JNK/c-Jun. The gene discussed is JUN; the disease is non-small cell lung carcinoma.